Organization
GlaxoSmithKline, Uxbridge, United Kingdom
2 abstracts
Abstract
A PHASE 3, OPEN-LABEL, CONTINUATION STUDY EVALUATING LONG-TERM SAFETY AND EFFICACY OF BELIMUMAB IN PATIENTS FROM JAPAN AND KOREA WITH SYSTEMIC LUPUS ERYTHEMATOSUS, FOR UP TO 7 YEARSOrg: University of Occupational and Environmental Health, Kitakyushu, Japan, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Rep. of (South Korea), GlaxoSmithKline, Collegeville, United States of America, GlaxoSmithKline (at the time of the study), Collegeville, United States of America, GlaxoSmithKline, Uxbridge, United Kingdom,
Abstract
BELIMUMAB, A BLYS-SPECIFIC INHIBITOR, SIGNIFICANTLY IMPROVED PHYSICAL FUNCTIONING, FATIGUE, AND OTHER HEALTH-RELATED QUALITY OF LIFE (HRQOL) MEASURES IN PATIENTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): BLISS-52 STUDY Org: SC Colentina, Bucharest, Romania, Hospital Britanico, Buenos Aires, HIGA San Martin, La Plata, Argentina, Monash Medical Center, Clayton, Australia, FOSCAL, Bucamaranga, Colombia,